Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

Williams, Bryan; M. MacDonald, Thomas; V. Morant, S.; J Webb, David; Sever, Peter; T. McInnes, Gordon; Ford, Ian; CRUICKSHANK, J.; J. Caulfield, Mark; Salsbury, Jackie; S. Mackenzie, Isla; Padmanabhan, Sandosh; J. Brown, Morris

doi:10.1016/s0140-6736(15)00257-3

Public

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

Published in The Lancet • Sep 20, 2015

Authors:

Bryan Williams

Thomas M. MacDonald

S. V. Morant

Abstract

BACKGROUND: Optimal drug treatment for patients with resistant hypertension is undefined. We aimed to test the hypotheses that resistant hypertension is most often caused by excessive sodium retention, and that spironolactone would therefore be superior to non-diuretic add-on drugs at lowering blood...

Subject

Spironolactone

Doxazosin

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!